Latest filings (excl ownership)
PRE 14A
Preliminary proxy
16 Apr 24
S-8
Registration of securities for employees
12 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
12 Mar 24
8-K
Departure of Directors or Certain Officers
28 Feb 24
SC TO-I/A
Issuer tender offer statement (amended)
28 Feb 24
SC TO-I
Issuer tender offer statement
30 Jan 24
SC TO-C
Information about tender offer
25 Jan 24
8-K
Other Events
25 Jan 24
424B3
Prospectus supplement
28 Nov 23
EFFECT
Notice of effectiveness
28 Nov 23
8-K
Departure of Directors or Certain Officers
22 Nov 23
CORRESP
Correspondence with SEC
22 Nov 23
UPLOAD
Letter from SEC
21 Nov 23
S-3
Shelf registration
17 Nov 23
8-K
Departure of Directors or Certain Officers
15 Nov 23
D
$92.15 mm in equity / options / securities to be acquired, sold $92.15 mm, 11 investors
7 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
2 Nov 23
8-K
Entry into a Material Definitive Agreement
25 Oct 23
8-K
Other Events
18 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
3 Aug 23
8-K
Other Events
1 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
25 Jul 23
DEFR14A
Revised proxy
2 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
4 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
S-8
Registration of securities for employees
9 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
9 Mar 23
UPLOAD
Letter from SEC
27 Dec 22
CORRESP
Correspondence with SEC
22 Dec 22
UPLOAD
Letter from SEC
8 Dec 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
2 Nov 22
Latest ownership filings
4
Matthew W. McClure
4 Mar 24
4
Lesley Ann Calhoun
4 Mar 24
4
Julian A. Symons
4 Mar 24
4
LAWRENCE BLATT
4 Mar 24
4
Peter Hirth
28 Feb 24
4
James Paul Scopa
28 Feb 24
4
Matthew W. McClure
28 Feb 24
4
Lesley Ann Calhoun
28 Feb 24
4
LAWRENCE BLATT
28 Feb 24
4
Julian A. Symons
28 Feb 24
4
Jack Nielsen
28 Feb 24
4
Carole Nuechterlein
28 Feb 24
4
Bridget A Martell
28 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
HHLR ADVISORS, LTD.
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
Alyeska Investment Group, L.P.
14 Feb 24
SC 13D/A
Versant Venture Capital VI, L.P.
8 Feb 24
SC 13G/A
ROCHE FINANCE LTD
7 Nov 23
3
Initial statement of insider ownership
7 Nov 23
SC 13D
BLATT LAWRENCE
6 Nov 23
SC 13G
Deep Track Capital, LP
2 Nov 23
4
Carole Nuechterlein
27 Oct 23
4
LAWRENCE BLATT
27 Oct 23
4
James Paul Scopa
27 Oct 23
4
Matthew W. McClure
12 Sep 23
4
Lesley Ann Calhoun
12 Sep 23
4
Lucinda Y. Quan
12 Sep 23
4
Julian A. Symons
12 Sep 23
4
LAWRENCE BLATT
12 Sep 23
4
Bridget A Martell
21 Jul 23
4
Jack Nielsen
21 Jul 23
4
Peter Hirth
21 Jul 23
4
James Paul Scopa
21 Jul 23
4
Carole Nuechterlein
21 Jul 23
4
Matthew W. McClure
17 Mar 23
4
Julian A. Symons
17 Mar 23
4
Lesley Ann Calhoun
17 Mar 23